既往治疗过的非霍奇金淋巴瘤患者接受苯达莫司汀治疗后的长期结局、第二恶性肿瘤及干细胞采集
该研究回顾三项临床试验的长期数据,分析149例既往接受过治疗的非霍奇金淋巴瘤患者使用苯达莫司汀的疗效与毒性;中位无事件生存期为14.1个月,中位随访8.9年期间23例患者发生25种癌症,包括8例骨髓增生异常综合征/急性髓系白血病;12次干细胞采集中9次成功。
要点
- 149例既往治疗的非霍奇金淋巴瘤患者,中位年龄60岁,中位既往治疗3线,中位无事件生存期14.1个月。
- 中位随访8.9年,23例患者发生25种癌症,其中8例为骨髓增生异常综合征/急性髓系白血病。
- 12次尝试干细胞采集中9次成功。
核心结论
- 这些严格收集的患者层面长期随访数据提供保证:苯达莫司汀或苯达莫司汀联合利妥昔单抗对复发或难治性惰性非霍奇金淋巴瘤患者具有疗效和安全性。
- 小部分但具有意义的患者在接受苯达莫司汀后获得持久缓解。
研究设计与样本
- 回顾三项临床试验的长期数据,纳入149例既往接受过治疗的非霍奇金淋巴瘤患者,来自21个中心。
- 中位年龄60岁(范围39-84岁),患者既往接受中位3线治疗。
- 组织学类型包括1-2级滤泡性淋巴瘤(n=73)、3级滤泡性淋巴瘤(n=23)、小淋巴细胞淋巴瘤(n=20)、边缘区淋巴瘤(n=15)、套细胞淋巴瘤(n=9)、转化型淋巴瘤(n=5)、淋巴浆细胞淋巴瘤(n=2)及未报告(n=2)。
主要发现
- 中位无事件生存期为14.1个月。
- 12次尝试干细胞采集中9次成功。
- 中位随访8.9年,23例患者发生25种癌症,包括8例骨髓增生异常综合征/急性髓系白血病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the long history of bendamustine as treatment for indolent non-Hodgkin lymphoma, long-term efficacy and toxicity data are minimal. We reviewed long-term data from three clinical trials to characterize the toxicity and efficacy of patients receiving bendamustine. Data were available for 149 subjects at 21 sites. The median age was 60 years at the start of bendamustine (range 39-84), and patients had received a median of 3 prior therapies. The histologies included grades 1-2 follicular lymphoma (FL; n = 73), grade 3 FL (n = 23), small lymphocytic lymphoma (n = 20), marginal zone lymphoma (n = 15), mantle cell lymphoma (n = 9), transformed lymphomas (n = 5), lymphoplasmacytic lymphoma (n = 2) and not reported (n = 2). The median event-free survival was 14·1 months. Nine of 12 attempted stem cell collections were successful. With a median follow-up of 8·9 years, 23 patients developed 25 cancers, including 8 patients with myelodysplastic syndrome/acute myeloid leukaemia. These data provide important information regarding the long-term toxicity of bendamustine in previously treated patients. A small but meaningful number of patients achieved durable remissions following bendamustine. These rigorously collected, patient-level, long-term follow-up data provide reassurance that bendamustine or bendamustine plus rituximab is associated with efficacy and safety for patients with relapsed or refractory indolent non-Hodgkin lymphoma.
引用
- Martin P, Chen Z, Cheson BD, et al. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. Br J Haematol. 2017. PMID: 28419413. doi:10.1111/bjh.14667
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。